Trial intelligence / Profile preview

Safety Profile of MVA-BN (Jynneos) Vaccine in PALM-007 Study Personnel

NCT05734508Phase 4Completed

Sponsor
National Institute of Allergy and Infectious Diseases
Start
Mar 2023
Primary completion
Jun 2024
Modality
Live Attenuated Vaccines
Countries
1
01

Overview

A Phase 4 trial of JYNNEOS in mpox, sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2023; status: completed.

02

Drugs

JYNNEOS
03

Conditions

mpox

Beyond the preview

Go deeper on NCT05734508.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05734508.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call